Earnings ·
Zomedica reports Q3 revenue of $9.9M, up 22% year-over-year
ZOMDFZomedica Corp.
Zomedica Corp. reported consolidated revenue of $9.9 million for the quarter ended September 30, 2026, a 22% increase from the prior year period and its strongest third-quarter result on record. Net loss narrowed to $3.2 million from $6.1 million in the same period last year, while operating expenses declined 21% to $9.5 million due to improved cost discipline. The company maintained a strong liquidity position with $40.9 million in cash and equivalents as of September 30, 2026. Zomedica is an animal health company offering innovative point-of-care diagnostic and therapeutic products for equine and companion animals.